Comparative Pharmacology
Head-to-head clinical analysis: SUPPRELIN LA versus TRELSTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUPPRELIN LA versus TRELSTAR.
SUPPRELIN LA vs TRELSTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SUPPRELIN LA is a sterile, biodegradable, subcutaneous implant containing histrelin acetate, a synthetic nonapeptide agonist of gonadotropin-releasing hormone (GnRH). After an initial transient increase, continuous administration results in downregulation of pituitary GnRH receptors, leading to suppressed luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing gonadal sex steroid production (testosterone in males, estradiol in females) to castrate levels.
Gonadotropin-releasing hormone (GnRH) agonist. Chronic administration suppresses pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, leading to reduced testicular and ovarian steroidogenesis.
50 mg subcutaneously once every 12 months (implant placed in inner upper arm).
3.75 mg intramuscularly once every 4 weeks or 11.25 mg intramuscularly once every 12 weeks or 22.5 mg intramuscularly once every 24 weeks.
None Documented
None Documented
Terminal half-life approximately 3-4 hours; clinical suppression of luteinizing hormone and testosterone sustained for 4 weeks due to depot formulation.
Terminal elimination half-life approximately 3 weeks (21-28 days) after intramuscular injection; sustained release formulation results in prolonged exposure.
Renal: <5% unchanged; hepatic metabolism; fecal elimination of metabolites.
Primarily hepatic metabolism; <5% excreted unchanged in urine; fecal elimination of metabolites accounts for approximately 20-30%.
Category C
Category C
GnRH Agonist
GnRH Agonist